BlackRock Fund Advisors’s CytomX Therapeutics CTMX Stock Holding History

BlackRock Fund Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$7.13M	Buy	648,924 +91,073	+16%	+$1.1M	﹤0.01%	2760
2016 Q3	$8.75M	Buy	557,851 +30,603	+6%	+$370K	﹤0.01%	2546
2016 Q2	$5.39M	Buy	527,248 +330,966	+169%	+$3.77M	﹤0.01%	2760
2016 Q1	$2.53M	Sell	196,282 -10,644	-5%	-$148K	﹤0.01%	3008
2015 Q4	$4.32M	Buy	+206,926	New	+$3.27M	﹤0.01%	2910

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Fund Advisors's CTMX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its CytomX Therapeutics (CTMX) stake by 16% in Q4 2016, buying an estimated $1.1M and bringing the position to 648,924 shares worth $7.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2760.

BlackRock Fund Advisors first reported a position in CTMX in Q4 2015 and has held it in 5 quarters since. The position peaked at $8.75M in Q3 2016. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2016.

BlackRock Fund Advisors held 648,924 shares of CytomX Therapeutics worth $7.13M as of Q4 2016.
BlackRock Fund Advisors bought 91,073 CytomX Therapeutics shares in Q4 2016, an estimated $1.1M.
CytomX Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2760 holding.
BlackRock Fund Advisors first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 5 quarters since.
BlackRock Fund Advisors's CytomX Therapeutics position peaked at $8.75M in Q3 2016.
68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.